Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pyrazinamide

FDA-approved product (tablet, oral), marketed as Pyrazinamide.

Registered studies
50+
Lab records
45
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Pyrazinamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK01; FDA class Antimycobacterial

Repurposing investigation

Pyrazinamide is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 45 lab records
Open Pyrazinamide in ChEMBL Registered studies below
Show the 45 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pyrazinamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

    NCT05401071 · start 2023-01-13

    Registered record
    Registry ID
    NCT05401071
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Short Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2023-01-13
    Completion
    2027-11-01
    Enrolment
    2,442

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionShort Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Azacytidine During Anti-tuberculosis Therapy

    NCT03941496 · start 2022-10

    Registered record
    Registry ID
    NCT03941496
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Azacitidine Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2022-10
    Completion
    2023-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionAzacitidine Injection
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

    NCT04738812 · start 2022-04-21

    Registered record
    Registry ID
    NCT04738812
    Conditions
    Tuberculosis; HIV-1-infection; Immuno-Deficiency
    Interventions
    Intensified TB treatment (initial phase); WHO standard TB treatment (initial phase)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-04-21
    Completion
    2025-11-12
    Enrolment
    1,330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV-1-infection; Immuno-Deficiency
    InterventionIntensified TB treatment (initial phase); WHO standard TB treatment (initial phase)
    PhasePhase 3
    Registry statusCompleted

  • Pharmacogenetics-guided Isoniazid Dosing in TB-HIV

    NCT05124678 · start 2021-12-07

    Registered record
    Registry ID
    NCT05124678
    Conditions
    Tuberculosis
    Interventions
    Isoniazid Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-12-07
    Completion
    2022-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid Tablets
    PhasePhase 2
    Registry statusUnknown

  • A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

    NCT04179500 · start 2021-09-16

    Registered record
    Registry ID
    NCT04179500
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis; Drug-Resistant Tuberculosis
    Interventions
    Pretomanid; Bedaquiline; moxifloxacin; pyrazinamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-16
    Completion
    2024-07-17
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis +1 more
    InterventionPretomanid; Bedaquiline; moxifloxacin; pyrazinamide
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

    NCT04518228 · start 2021-09-01

    Registered record
    Registry ID
    NCT04518228
    Conditions
    HIV; Tuberculosis
    Interventions
    Bictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG); Atazanavir/ritonavir (ATV/r); Darunavir/ritonavir (DRV/r); Lopinavir/ritonavir (LPV/r); Cobicistat; Ritonavir; First-Line TB Treatment; Second-Line TB Treatment; Doravirine (DOR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-09-01
    Completion
    2025-07-10
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionBictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG) +8 more
    PhaseNot recorded
    Registry statusTerminated

  • Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

    NCT04951986 · start 2021-08-11

    Registered record
    Registry ID
    NCT04951986
    Conditions
    Disseminated Tuberculosis; HIV
    Interventions
    Rifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-11
    Completion
    2026-03
    Enrolment
    732

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisseminated Tuberculosis; HIV
    InterventionRifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Pharmacokinetic Study of Linezolid for TB Meningitis

    NCT03537495 · start 2021-06-21

    Registered record
    Registry ID
    NCT03537495
    Conditions
    Tuberculosis, Meningeal; Linezolid
    Interventions
    Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-06-21
    Completion
    2023-07-20
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Meningeal; Linezolid
    InterventionLinezolid
    PhasePhase 2
    Registry statusCompleted

  • Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

    NCT04145258 · start 2021-02-07

    Registered record
    Registry ID
    NCT04145258
    Conditions
    Tuberculous Meningitis
    Interventions
    Aspirin; Placebo of aspirin; WHO TBM treatment; Intensified TBM treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-02-07
    Completion
    2026-09-26
    Enrolment
    768

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculous Meningitis
    InterventionAspirin; Placebo of aspirin; WHO TBM treatment; Intensified TBM treatment
    PhasePhase 3
    Registry statusRecruiting

  • Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

    NCT04485156 · start 2020-09

    Registered record
    Registry ID
    NCT04485156
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    High-dose rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2020-09
    Completion
    2026-12
    Enrolment
    926

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionHigh-dose rifampicin; Isoniazid; Pyrazinamide; Ethambutol +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

    NCT04176250 · start 2020-01-16

    Registered record
    Registry ID
    NCT04176250
    Conditions
    Pulmonary Tuberculosis
    Interventions
    TBA-7371; TBA-7371; TBA-7371; TBA-7371; TBA-7371; HRZE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-16
    Completion
    2022-10-05
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionTBA-7371; TBA-7371; TBA-7371; TBA-7371 +2 more
    PhasePhase 2
    Registry statusCompleted

  • Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM

    NCT03927313 · start 2019-06-12

    Registered record
    Registry ID
    NCT03927313
    Conditions
    Tuberculosis Meningitis; HIV-1-infection
    Interventions
    Linezolid; High dose rifampicin; Aspirin; Standard of Care anti-tuberculous therapy; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-06-12
    Completion
    2021-03-31
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Meningitis; HIV-1-infection
    InterventionLinezolid; High dose rifampicin; Aspirin; Standard of Care anti-tuberculous therapy +1 more
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

    NCT03982277 · start 2019-04-30

    Registered record
    Registry ID
    NCT03982277
    Conditions
    Tuberculosis
    Interventions
    Rifampin 300 Mg Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-30
    Completion
    2021-07-23
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifampin 300 Mg Oral Capsule
    PhasePhase 2
    Registry statusCompleted

  • The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT03830671 · start 2019-03-08

    Registered record
    Registry ID
    NCT03830671
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    18-month regimen containing 6 anti-TB drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-08
    Completion
    2022-06-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    Intervention18-month regimen containing 6 anti-TB drugs
    PhasePhase 4
    Registry statusCompleted

  • Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet

    NCT03800381 · start 2019-01-28

    Registered record
    Registry ID
    NCT03800381
    Conditions
    Tuberculosis; Human Immunodeficiency Virus; Coinfection
    Interventions
    Observational PK study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-28
    Completion
    2024-08-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus; Coinfection
    InterventionObservational PK study
    PhaseNot recorded
    Registry statusCompleted